Alphamab Advances First PD-L1 x VEGFR2 Antibody-Drug Conjugate JSKN027 Into Clinical Trials
Key Insights
Alphamab (search)'s JSKN027 (search) represents the first anti-PD-L1 (search) x VEGFR2 (search) bispecific antibody-drug conjugate to enter clinical development, scheduled to begin trials in March 2026.
The novel ADC combines topoisomerase 1 inhibitor payload with dual immune checkpoint and angiogenesis inhibition mechanisms of action.
Huabo Biopharm (search) advances sotiburafusp alfa into phase 3 trials for first-line squamous NSCLC (search), reporting 84% response rates in early studies.
Alphamab (search) has positioned itself at the forefront of next-generation cancer immunotherapy with JSKN027 (search), the first anti-PD-L1 (search) x VEGFR2 (search) bispecific antibody-drug conjugate (ADC) set to enter clinical trials in March 2026. The innovative approach combines the established benefits of immune checkpoint inhibition and anti-angiogenic therapy with the targeted cytotoxic potential of ADC technology.
Novel ADC Architecture Targets Dual Pathways
JSKN027 (search) employs a sophisticated design that targets both PD-L1 (search) and VEGFR2 (search), similar to other bispecifics in development but with the added advantage of ADC functionality. The molecule utilizes a topoisomerase 1 inhibitor payload conjugated to the monoclonal antibody's Fc region at an average antibody-to-drug ratio of 4, connected through a cleavable linker.
The company first disclosed development of this molecule last year, with China's regulatory authority accepting the investigational new drug application in December. Alphamab (search) argues that JSKN027 (search) offers multiple mechanisms of action, including targeted and bystander ADC activity alongside inhibition of tumor angiogenesis through VEGF (search)/VEGFR2 (search) signaling blockade.
The structural approach mirrors aspects of BioNTech/Bristol Myers Squibb (search)'s pumitamig (search) by targeting PD-L1 (search) rather than PD-1 (search), potentially allowing the molecule to anchor to tumor cells while blocking PD-1/PD-L1 interactions. The VEGFR2 (search) selectivity, similar to Ottimo (search)'s jankistomig, may help minimize VEGF (search)-related side effects.
Competitive Landscape Intensifies
The PD-(L)1 x VEGF (search) bispecific field continues expanding rapidly, with no fewer than five naked monoclonal antibodies currently in pivotal trials for lung cancer alone. Huabo Biopharm (search) has advanced its PD-L1 (search) x VEGF fusion protein sotiburafusp alfa into phase 3 development, posting the first late-stage study for evaluation in first-line squamous non-small cell lung cancer (search) (NSCLC).
Sotiburafusp alfa, a recombinant humanized fusion protein combining an anti-PD-L1 (search) monoclonal antibody fused to VEGFR-1, will be tested head-to-head against pembrolizumab plus chemotherapy. The phase 3 trial HB0025-C-0302 uses progression-free survival as the primary endpoint, with patients stratified by PD-L1 expression levels and excluding those with EGFR (search) and ALK (search) pathway mutations.
Promising Early Efficacy Data
Huabo presented compelling efficacy data at last year's ESMO conference, reporting an 84% response rate in 62 treatment-naive patients with squamous NSCLC (search) treated with sotiburafusp alfa. Response rates reached 100% in patients with PD-L1 (search) expression of at least 50%, though all observed responses were partial.
However, safety considerations remain important, with grade ≥3 treatment-related adverse events occurring in 40% of patients and two treatment-related deaths reported. The lung cancer results build on similarly strong data in endometrial cancer (search), where Huabo reported an 84% response rate at ASCO.
Expanding Development Pipeline
The field now encompasses multiple structural approaches beyond traditional bispecifics. Doer Biotechnology (search) is developing DR30206, a triple-target fusion protein designed to inhibit PD-L1 (search), TGF-β (search), and VEGF (search), currently in phase 3 trials for gastric cancer (search) in China.
BioNTech has posted a new phase 3 trial of pumitamig (search) in first-line lung cancer, Rosetta-Lung202, focusing exclusively on patients with PD-L1 (search) expression of 50% or higher. Nine pivotal trials of the PD-L1 x VEGF (search) bispecific are now listed on clinicaltrials.gov, with additional studies planned in first-line head and neck cancer (search).
The emergence of JSKN027 (search) as the first ADC in this class represents a significant evolution in the field, potentially offering enhanced tumor-killing capability through its cytotoxic payload while maintaining the dual pathway inhibition that has shown promise across multiple tumor types.